Hepatitis B Vaccines Authorized for 19-Year-Olds
For a 19-year-old, five hepatitis B vaccines are authorized: Recombivax HB, Engerix-B, Heplisav-B, PreHevbrio, and Twinrix (combination hepatitis A and B vaccine). 1, 2
Standard Vaccine Options and Dosing
Three-Dose Vaccines (0,1,6-month schedule)
Recombivax HB: 10 μg (1.0 mL) per dose for adults aged ≥20 years, administered at 0,1, and 6 months 1, 2
Engerix-B: 20 μg (1.0 mL) per dose for adults aged ≥20 years, administered at 0,1, and 6 months 1, 2, 3
PreHevbrio: 10 μg (1.0 mL) per dose for adults aged ≥18 years, administered at 0,1, and 6 months 1, 2
- This is a three-antigen hepatitis B vaccine approved by the FDA in 2021 1
Two-Dose Vaccine (0,1-month schedule)
- Heplisav-B: 20 μg (0.5 mL) per dose for adults aged ≥18 years, administered at 0 and 1 month 1, 2
- This vaccine offers the advantage of faster completion with only two doses over one month, potentially improving compliance 5
Combination Vaccine
- Twinrix: Combines hepatitis A and hepatitis B antigens (20 μg hepatitis B component per 1.0 mL injection) 2
Universal Vaccination Recommendation
- All adults aged 19-59 years are now recommended to receive hepatitis B vaccination, removing the previous requirement for risk factor assessment 1, 6
- This universal recommendation eliminates the need for risk factor screening and disclosure, which should increase vaccination coverage 1
Special Considerations for 19-Year-Olds
- A 19-year-old falls within the universal vaccination age range and should receive hepatitis B vaccination regardless of risk factors 1
- All five vaccine options are appropriate for this age group, with the choice depending on factors such as desired schedule completion time, pregnancy status (if applicable), and specific clinical circumstances 1, 2
Important Caveats
- If the patient is pregnant: Only use Engerix-B, Recombivax HB, or Twinrix, as Heplisav-B and PreHevbrio have insufficient safety data in pregnancy 1, 2
- If the patient is on hemodialysis: Do not use Heplisav-B or PreHevbrio, as their safety and effectiveness have not been established in this population 1
- Pre-vaccination serologic testing is not required and should not delay vaccination, though it may be cost-effective in populations with high rates of previous infection 1